Loading clinical trials...

CS1P1 PET Studies of Neuroinflammation in Parkinson Disease | Clinical Trials | Clareo Health

ENROLLING_BY_INVITATION

CS1P1 PET Studies of Neuroinflammation in Parkinson Disease

NCT06084533•Washington University School of Medicine

Summary

Parkinson disease (PD) is a progressive neurological disorder strongly linked to advancing age that results in decline in mobility and thinking. Based on prior research, the investigators think that small amounts of inflammation in the brain may contribute to the mobility and thinking problems in people with PD. They are trying to measure inflammation in the brain in order to understand how this inflammation could be contributing to the symptoms of PD. This study involves a brain positron emission tomography (PET) scan with a new, investigational radioactive tracer called \[11C\]-CS1P1 to identify inflammation in the brain.The goal of this project is to quantify neuroinflammation with \[11C\]-CS1P1 PET and compare to motor and cognitive function in participants with various stages of severity of PD compared to controls.

Eligibility

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Parkinson Disease (PD) participants must be at least 50 years old and meet clinical diagnostic criteria of idiopathic PD.
•Control participants must be at least 50 years old and not have PD, no first-degree family member with PD, and no evidence of PD or dementia on examination.

Exclusion Criteria

•any history of other neurologic illness (e.g. stroke, seizure, multiple sclerosis)
•history of brain surgery or major head trauma
•major medical/systemic illness
•severe psychiatric illness (e.g. bipolar disorder, schizophrenia)
•major drug abuse
•history of long term use of anti-dopaminergic medication
•chronic treatment with immunomodulatory or anti-inflammatory medications
•weight over 300 lbs
•contraindication to or inability to tolerate MRI

Locations (1)

Washington University School of Medicine

St Louis, Missouri, United States

Key Dates

Start Date

January 10, 2024

Primary Completion Date

February 1, 2029

Completion Date

February 28, 2029

Last Updated

March 28, 2025

Enrollment

ESTIMATED participants

Conditions

Parkinson Disease

Interventions

[11C]-CS1P1

DRUG

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

RECRUITINGNA

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

NCT06692920

Parkinson Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 28, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

CS1P1 PET Studies of Neuroinflammation in Parkinson Disease

Inclusion Criteria

Exclusion Criteria

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

Montelukast in Parkinson Disease

Exercise for Cognitive Excellence in Parkinson's Disease

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients